Henry L - Search Results

1

Epidemiology of NAFLD - Focus on diabetes.

Younossi ZM, Henry L. Younossi ZM, et al. Among authors: henry l. Diabetes Res Clin Pract. 2024 Apr;210:111648. doi: 10.1016/j.diabres.2024.111648. Epub 2024 Apr 2. Diabetes Res Clin Pract. 2024. PMID: 38569945

2

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.

Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Younossi ZM, et al. Among authors: henry l. J Hepatol. 2014 Mar;60(3):530-7. doi: 10.1016/j.jhep.2013.11.009. Epub 2013 Nov 19. J Hepatol. 2014. PMID: 24269472

3

A new comorbidity model for predicting mortality in patients with cirrhosis: does it work?

Younossi ZM, Henry L, Stepanova M. Younossi ZM, et al. Among authors: henry l. Gastroenterology. 2014 Jan;146(1):19-24. doi: 10.1053/j.gastro.2013.11.026. Epub 2013 Nov 25. Gastroenterology. 2014. PMID: 24287302 No abstract available.

4

Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S. Younossi ZM, et al. Among authors: henry l. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6. Clin Gastroenterol Hepatol. 2014. PMID: 24316172

5

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Nader F, Hunt S. Younossi ZM, et al. Among authors: henry l. J Hepatol. 2014 Apr;60(4):741-7. doi: 10.1016/j.jhep.2013.12.006. Epub 2013 Dec 11. J Hepatol. 2014. PMID: 24333184 Clinical Trial.

6

Monitoring and treatment of inactive chronic hepatitis B: is it cost-effective?

Younossi Z, Henry L. Younossi Z, et al. Among authors: henry l. Hepatology. 2014 Jul;60(1):19-21. doi: 10.1002/hep.27062. Epub 2014 May 27. Hepatology. 2014. PMID: 24504789 No abstract available.

7

Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease.

Younossi ZM, Zheng L, Stepanova M, Henry L, Venkatesan C, Mishra A. Younossi ZM, et al. Among authors: henry l. J Clin Gastroenterol. 2015 Mar;49(3):222-7. doi: 10.1097/MCG.0000000000000071. J Clin Gastroenterol. 2015. PMID: 24637730

8

Reply to: "Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right".

Younossi ZM, Henry L, Singer M. Younossi ZM, et al. Among authors: henry l. J Hepatol. 2014 Aug;61(2):454-5. doi: 10.1016/j.jhep.2014.05.006. Epub 2014 May 10. J Hepatol. 2014. PMID: 24824281 Free article. No abstract available.

9

Sofosbuvir (Sovaldi) for the treatment of hepatitis C.

Lam B, Henry L, Younossi Z. Lam B, et al. Among authors: henry l. Expert Rev Clin Pharmacol. 2014 Sep;7(5):555-66. doi: 10.1586/17512433.2014.928196. Epub 2014 Jun 11. Expert Rev Clin Pharmacol. 2014. PMID: 24918162 Review.

10

Hepatitis. Chronic HCV infection, diabetes and liver-related outcomes.

Henry L, Younossi Z. Henry L, et al. Nat Rev Gastroenterol Hepatol. 2014 Sep;11(9):520-1. doi: 10.1038/nrgastro.2014.122. Epub 2014 Jul 15. Nat Rev Gastroenterol Hepatol. 2014. PMID: 25023031

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,481 results

Search Page